How PBMs distort and undermine specialty drug pricing guarantees
Ben LinkSpecialty, WAC, AWP, specialty drugs, PBM, Brand drugs, Generic drugs, Effective rate, NADAC, Linda Cahn, CVS, Express Scripts, Optum, Emgality, Retevmo, Imatinib, Gleevec, Hyalgan, Medicaid, Medicare, Mark Cuban, Ohio
Brand drug launch prices: A game of perspective
Ben LinkRebates, Launch, drug prices, Brand drugs, Inflation Reduction Act, Medicare, Lyrica, WAC, Adbry, Firazyr, Zolgensma, Trikafta, CPI, List prices
Medicare hits $200 billion in gross drug spend: Who gets the blame?
Ben LinkMedicare, Part D, Brand drugs, Generic drugs, Specialty, DIR fees, Rebates, PBM, Eliquis, Revlimid, Xarelto, Januvia, Trulicity, Imbruvica, Lantus, Jardiance, Humira, Ibrance, NADAC, atorvastatin, WAC
Wreck-fidera: How Medicare Part D has hidden the benefits of generic competition for a blockbuster Multiple Sclerosis treatment
Ben LinkMedicare, Copaxone, Teva, Rebates, Tecfidera, Biogen, Multiple Sclerosis, WAC, Mylan, NADAC, specialty drugs, Kaiser, CVS, UnitedHealthcare, Cigna, Anthem, Humana, Centene, DIR fees, AWP, Plan Finder
The Rise of the Drug Mix Empire
International reference pricing: Discounts Down Under far surpass U.S. drug price concessions
Ben LinkAustralia, International pricing, PBM, NADAC, Eliquis, Rebates, Advair, Fluticasone, Gleevec, Imatinib, Part D, Part B, Aetna, Albuterol
The Flawed Design of Medicare Part D: A Copaxone Case Study
Ben LinkCopaxone, glatiramer, Medicare, Part D, PBM, specialty drugs, Gleevec, ACA, Drug prices, Teva, Mylan, Sandoz, Deductible, Rebates, DIR fees
Two new dashboards released to assist with drug shortage research
Ben LinkCOVID-19, China, India, FDA, Drug shortages, drug prices, NADAC, Omeprazole, Medicaid, Prilosec, Lisinopril, Epclusa, sofosbuvir, naproxen, hydrocodone, ranitidine, hydroxychloroquine
Drug pricing's $268 billion non-event
